Medicus Pharma Ltd. MDCX
Medicus Pharma Ltd. (Nasdaq: MDCX) is an oncology drug developer. Its lead program, CD228V (PF-08046031), is in Phase 1 for melanoma, particularly relapsed or refractory disease. Its next catalyst on record is CD228V: clinical proof-of-concept in melanoma, supported by existing U.S. IND and first-in-human Phase 1 clinical study (NCT06799533) (date not stated).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: CD228V — clinical proof-of-concept in melanoma, supported by existing U.S. IND and first-in-human Phase 1 clinical study (NCT06799533) (date not stated). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| SkinJect (D-MNA patch with doxorubicin) | basal cell carcinoma in Gorlin Syndrome patients | device-combination | Phase 2 |
| Teverelix | advanced prostate cancer at increased cardiovascular risk | protein/peptide | Phase 2 |
| Teverelix | acute urinary retention (AUR) prevention in benign prostatic hyperplasia | protein/peptide | Phase 2 |
| Teverelix | symptomatic endometriosis | protein/peptide | Phase 2 |
| CD228V (PF-08046031) | melanoma | antibody | Phase 1 |
Recent results and decisions
- Nov 14, 2025started First patient treated in October 2025 in the SKNJCT-004 randomized study in the UAE (36 patients planned).
In October 2025, the Company treated its first patient in the clinical study (SKNJCT-004) currently underway in the United Arab Emirates (UAE).
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
- Erasca, Inc. ERAS
- Parabilis Medicines, Inc. PBLS
- Xencor Inc XNCR
- Schrodinger, Inc. SDGR
- Vir Biotechnology, Inc. VIR
- Zymeworks Inc. ZYME
- Janux Therapeutics, Inc. JANX
- Aktis Oncology, Inc. AKTS
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.